References
- Colonna M, Samaridis J, Angman L. Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. Eur J Immunol 2000;30(2):697–704. https://doi.org/10.1002/1521-4141(200002)30:2<697::AID-IMMU697>3.0.CO;2-M
- Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors GPVI and CLEC-2. J Clin Invest 2019;129(1):12–23. https://doi.org/10.1172/JCI122955
- Suzuki-Inoue K, Fuller GL, Garcia A, Eble JA, Pohlmann S, Inoue O, Gartner TK, Hughan SC, Pearce AC, Laing GD, et al. A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood. 2006;107(2):542–549. https://doi.org/10.1182/blood-2005-05-1994
- Christou CM, Pearce AC, Watson AA, Mistry A, Pollitt A, Fenton-May A, Johnson L, Jackson D, Watson S, O’callaghan C, et al. Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J 2008;411(1):133–140. https://doi.org/10.1042/BJ20071216
- Bourne J, Colicchia M, Di Y, Martin E, Slater A, Roumenina LT, Dimitrov JD, WatsonSP, Rayes J. Heme Induces Human and Mouse Platelet Activation through C-type-lectin-like Receptor CLEC-2. Haematologica 2021;106(2):626-629. 10.3324/haematol.2020.246488
- Hitchcock JR, Cook CN, Bobat S, Ross EA, Flores-Langarcia A, Lowe KL, Khan M, Dominguez-Medina CC, Lax S, Carvalho-Gaspar M, et al. Inflammation drives thrombosis after Salmonella infection via CLEC-2 on platelets. J Clin Invest 2020;106(1):4429–4446. https://doi.org/10.1172/JCI79070
- Payne H, Ponomaryov T, Watson SP, Brill A. Mice with a deficiency in CLEC-2 are protected against deep vein thrombosis. Blood. 2017;129(14):2013–2020. https://doi.org/10.1182/blood-2016-09-742999
- Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, Eto K, Kashiwagi H, Tomiyama Y, Yatomi Y, Umemura K, et al. Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 2010;285(32):24494–24507. https://doi.org/10.1074/jbc.M110.130575
- Haining EJ, Nicolson PLR, Onselaer MB, Poulter NS, Rayes J, Thomas MR, Watson SP. GPVI and CLEC-2. In: Michelson AD, editor. Platelets. 4th. Cambridge (MA): Elsevier; 2019. p. 213–226
- Suzuki-Inoue K, Osada M, Ozaki Y. Physiologic and pathophysiologic roles of interaction between C-type lectin-like receptor 2 and podoplanin: partners from in utero to adulthood. J Thromb Haemost 2017;15(2):219–229. https://doi.org/10.1111/jth.13590
- Damaskinaki FN, Moran LA, Garcia A, Kellam B, Watson SP. Overcoming challenges in developing small molecule inhibitors for GPVI and CLEC-2. Platelets 2021;32(6):744–752. https://doi.org/10.1080/09537104.2020.1863939
- Watson AA, Brown J, Harlos K, Eble JA, Walter TS, O’Callaghan CA. The crystal structure and mutational binding analysis of the extracellular domain of the platelet-activating receptor CLEC-2. J Biol Chem. 2007;282(5):3165–3172. https://doi.org/10.1074/jbc.M610383200
- Nagae M, Morita-Matsumoto K, Kato M, Kaneko MK, Kato Y, Yamaguchi Y. A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure 2014;22(12):1711–1721. https://doi.org/10.1016/j.str.2014.09.009
- Zhou L, Qian Y, Zhang X, Ruan Y, Ren S, Gu J. Elucidation of differences in N-glycosylation between different molecular weight forms of recombinant CLEC-2 by LC MALDI tandem MS. Carbohydr Res 2015; 402:180–188. https://doi.org/10.1016/j.carres.2014.07.005
- Watson AA, Christou CM, James JR, Fenton-May AE, Moncayo GE, Mistry AR, Davis SJ, Gilbert RJC, Chakera A, O’Callaghan CA, et al. The platelet receptor CLEC-2 is active as a dimer. Biochemistry 2009; 48(46):10988–10996.https://doi.org/10.1021/bi901427d
- Hughes CE, Sinha U, Pandey A, Eble JA, O’Callaghan CA, Watson SP. Critical Role for an acidic amino acid region in platelet signaling by the HemITAM (hemi-immunoreceptor tyrosine-based activation motif) containing receptor CLEC-2 (C-type lectin receptor-2). J Biol Chem 2013;288(7):5127–5135. https://doi.org/10.1074/jbc.M112.411462
- Gitz E, Pollitt AY, Gitz-Francois JJ, Alshehri O, Mori J, Montague S, Nash GB, Douglas MR, Gardiner EE, Andrews RK, et al. CLEC-2 expression is maintained on activated platelets and on platelet microparticles. Blood 2014;124(14):2262–2270. https://doi.org/10.1182/blood-2014-05-572818
- Burkhart JM, Vaudel M, Gambaryan S, Radau S, Walter U, Martens L, Geiger J, Sickmann A, Zahedi RP. The first comprehensive and quantitative analysis of human platelet protein composition allows the comparative analysis of structural and functional pathways. Blood 2012;120(15):e73–82. https://doi.org/10.1182/blood-2012-04-416594
- Zeiler M, Moser M, Mann M. Copy number analysis of the murine platelet proteome spanning the complete abundance range. Mol Cell Proteomics 2014;13(12):3435–3445. https://doi.org/10.1074/mcp.M114.038513
- Dunster JL, Unsworth AJ, Bye AP, Haining EJ, Sowa MA, Di Y, Sage T, Pallini C, Pike JA, Hardy AT, et al. Interspecies differences in protein expression do not impact the spatiotemporal regulation of glycoprotein VI mediated activation. J Thromb Haemost 2020;18(2):485–496. https://doi.org/10.1111/jth.14673
- Senis YA, Tomlinson MG, Garcia Á, Dumon S, Heath VL, Herbert J, Cobbold SP, Spalton JC, Ayman S, Antrobus R, et al. A comprehensive proteomics and genomics analysis reveals novel transmembrane proteins in human platelets and mouse megakaryocytes including G6b-B, a novel immunoreceptor tyrosine-based inhibitory motif protein. Mol Cell Proteomics 2007;6(3):548–564. https://doi.org/10.1074/mcp.D600007-MCP200
- Haining EJ, Cherpokova D, Wolf K, Becker IC, Beck S, Eble JA, Stegner D, Watson SP, Nieswandt B. CLEC-2 contributes to hemostasis independently of classical hemITAM signaling in mice. Blood 2017; 130(20):2224–2228.https://doi.org/10.1182/blood-2017-03-771907
- Pollitt AY, Grygielska B, Leblond B, Desire L, Eble JA, Watson SP. Phosphorylation of CLEC-2 is dependent on lipid rafts, actin polymerization, secondary mediators, and Rac. Blood 2010; 115(14): 2938–2946. https://doi.org/10.1182/blood-2009-12-257212
- Borgognone A, Navarro-Nunez L, Correia JN, Pollitt AY, Thomas SG, Eble JA, Pulcinelli FM, Madhani M, Watson SP. CLEC-2-dependent activation of mouse platelets is weakly inhibited by cAMP but not by cGMP. J Thromb Haemost 2017; 15(2): 550–559.https://doi.org/10.1111/jth.12514
- Izquierdo I, Barrachina MN, Hermida-Nogueira L, Casas V, Moran LA, Lacerenza S, Pinto-Llorente R, Eble JA, de Los Rios V, Domniguez E, et al. A comprehensive tyrosine phosphoproteomic analysis reveals novel components of the platelet CLEC-2 signaling cascade. Thromb Haemost 2020;120(2):262–276. https://doi.org/10.1055/s-0039-3400295
- Lombard SE, Pollitt AY, Hughes CE, Di Y, Mckinnon T, O’callaghan CA, Watson SP. Mouse podoplanin supports adhesion and aggregation of platelets under arterial shear: a novel mechanism of haemostasis. Platelets 2018;29(7):716–722. https://doi.org/10.1080/09537104.2017.1356919
- Hughes CE, Pollitt AY, Mori J, Eble JA, Tomlinson MG, Hartwig JH, O’Callaghan CA, Fütterer K, Watson SP. CLEC-2 activates Syk through dimerization. Blood 2010;115(14):2947–2955. https://doi.org/10.1182/blood-2009-08-237834
- Pollitt AY, Poulter NS, Gitz E, Navarro-Nuñez L, Wang Y-J, Hughes CE, Thomas SG, Nieswandt B, Douglas MR, Owen DM, et al. Syk and Src family kinases regulate C-type lectin receptor 2 (CLEC-2)-mediated clustering of podoplanin and platelet adhesion to lymphatic endothelial cells. J Biol Chem 2014;289(52):35695–35710. https://doi.org/10.1074/jbc.M114.584284
- Sancho D, Mourao-Sa D, Joffre OP, Schulz O, Rogers NC, Pennington DJ, Carlyle JR, Reis E Sousa C. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest 2008; 118(6):2098–2110. https://doi.org/10.1172/JCI34584
- Natarajan K, Sawicki MW, Margulies DH, Mariuzza RA. Crystal structure of human CD69: A C-type lectin-like activation marker of hematopoietic cells. Biochemistry 2000;39(48):14779–14786. https://doi.org/10.1021/bi0018180
- Park H, Adsit FG, Boyington JC. The 1.4 Å crystal structure of the human oxidized low density lipoprotein receptor lox-1. J Biol Chem 2005;280(14):13593–13599. https://doi.org/10.1074/jbc.M500768200
- De Winde CM, Matthews AL, Van Deventer S, Van Der Schaaf A, Tomlinson ND, Jansen E, Eble JA, Nieswandt B, McGettrick HM, Figdor CG, et al. C-type lectin-like receptor 2 (CLEC-2)-dependent dendritic cell migration is controlled by tetraspanin CD37. J Cell Sci 2018;131(19):19.https://doi.org/10.1242/jcs.214551
- Clark JC, Damaskinaki FN, Cheung YFH, Slater A, Watson SP. Structure-function relationship of the platelet glycoprotein VI (GPVI) receptor: does it matter if it is a dimer or monomer? Platelets 2021;32(6):724–732. https://doi.org/10.1080/09537104.2021.1887469
- Manne BK, Badolia R, Dangelmaier C, Eble JA, Ellmeier W, Kahn M, Kunapuli SP. Distinct pathways regulate Syk protein activation downstream of immune tyrosine activation motif (ITAM) and hemITAM receptors in platelets. J Biol Chem 2015;290(18):11557–11568. https://doi.org/10.1074/jbc.M114.629527
- Fuller GLJ, Williams JAE, Tomlinson MG, Eble JA, Hanna SL, Pöhlmann S, Suzuki-Inoue K, Ozaki Y, Watson SP, Pearce AC, et al. The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. J Biol Chem 2007;282(17):12397–12409. https://doi.org/10.1074/jbc.M609558200
- Hughes CE, Finney BA, Koentgen F, Lowe KL, Watson SP. The N-terminal SH2 domain of Syk is required for (hem)ITAM, but not integrin, signaling in mouse platelets. Blood 2015;125(1):144–154. https://doi.org/10.1182/blood-2014-05-579375
- Martyanov AA, Balabin FA, Dunster JL, Panteleev MA, Gibbins JM, Sveshnikova AN. Control of platelet CLEC-2-mediated activation by receptor clustering and tyrosine kinase signaling. Biophys J 2020; 118(11):2641–2655. https://doi.org/10.1016/j.bpj.2020.04.023
- Severin S, Pollitt AY, Navarro-Nunez L, Nash CA, Mourão-Sá D, Eble JA, Senis YA, Watson SP. Syk-dependent phosphorylation of CLEC-2: a novel mechanism of hem-immunoreceptor tyrosine-based activation motif signaling. J Biol Chem 2011;286(6):4107–4116. https://doi.org/10.1074/jbc.M110.167502
- Manne BK, Badolia R, Dangelmaier CA, Kunapuli SP. C-type lectin like receptor 2 (CLEC-2) signals independently of lipid raft microdomains in platelets. Biochem Pharmacol 2015;93(2):163–170. https://doi.org/10.1016/j.bcp.2014.11.005
- Nicolson PLR, Nock SH, Hinds J, Garcia-Quintanilla L, Smith CW, Campos J, Brill A, Pike JA, Khan AO, Poulter NS, et al. Low-dose Btk inhibitors selectively block platelet activation by CLEC-2. Haematologica 2021; 106(1): 208–219.https://doi.org/10.3324/haematol.2019.218545
- Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369(1):32–42.https://doi.org/10.1056/NEJMoa1215637
- Cooper JA, Qian H. A mechanism for SRC kinase-dependent signaling by noncatalytic receptors. Biochemistry 2008;47(21):5681–5688. https://doi.org/10.1021/bi8003044
- Park MJ, Sheng R, Silkov A, Jung D-J, Wang Z-G, Xin Y, Kim H, Thiagarajan-Rosenkranz P, Song S, Yoon Y, et al. SH2 domains serve as lipid-binding modules for pTyr-signaling proteins. Mol Cell 2016; 62(1): 7–20.https://doi.org/10.1016/j.molcel.2016.01.027
- Shin Y, Morita T. Rhodocytin, a functional novel platelet agonist belonging to the heterodimeric C-type lectin family, induces platelet aggregation independently of glycoprotein Ib. Biochem Biophys Res Commun 1998;245(3):741–745. https://doi.org/10.1006/bbrc.1998.8516
- Watson AA, Eble JA, O’Callaghan CA. Crystal structure of rhodocytin, a ligand for the platelet-activating receptor CLEC-2. Protein Sci 2008;17(9):1611–1616. https://doi.org/10.1110/ps.035568.108
- Hooley E, Papagrigoriou E, Navdaev A, Pandey AV, Clemetson JM, Clemetson KJ, Emsley J. The crystal structure of the platelet activator aggretin reveals a novel (alphabeta)2 dimeric structure. Biochemistry 2008;47(30):7831–7837. https://doi.org/10.1021/bi800528t
- Mizuno H, Fujimoto Z, Koizumi M, Kano H, Atoda H, Morita T. Structure of coagulation factors IX/X-binding protein, a heterodimer of C-type lectin domains. Nat Struct Biol 1997;4(6):438–441. https://doi.org/10.1038/nsb0697-438
- Sasaki T, Shirai T, Tsukiji N, Otake S, Tamura S, Ichikawa J, Osada M, Satoh K, Ozaki Y, Suzuki‐Inoue K, et al. Functional characterization of recombinant snake venom rhodocytin: rhodocytin mutant blocks CLEC-2/podoplanin-dependent platelet aggregation and lung metastasis. J Thromb Haemost 2018; 16(5):960–972. https://doi.org/10.1111/jth.13987
- Quintanilla M, Montero-Montero L, Renart J, Martin-Villar E. Podoplanin in Inflammation and Cancer. Int J Mol Sci 2019;20:3. https://doi.org/10.3390/ijms20030707
- Pula B, Witkiewicz W, Dziegiel P, Podhorska-Okolow M. Significance of podoplanin expression in cancer-associated fibroblasts: a comprehensive review. Int J Oncol 2013;42(6):1849–1857. https://doi.org/10.3892/ijo.2013.1887
- Krishnan H, Rayes J, Miyashita T, Ishii G, Retzbach EP, Sheehan SA, Takemoto A, Chang YW, Yonada K, Asai J, et al. Podoplanin: an emerging cancer biomarker and therapeutic target. Cancer Science 2012;120(15):1292–1299. https://doi.org/10.1111/cas.13580
- Rayes J, Bourne JH, Brill A, Watson SP. The dual role of platelet-innate immune cell interactions in thrombo-inflammation. Res Pract Thromb Haemost 2020;4(1):23–35. https://doi.org/10.1002/rth2.12266
- Fu J, Gerhardt H, McDaniel JM, Xia B, Liu X, Ivanciu L, Ny A, Hermans K, Silasi-Mansat R, McGee S, et al. Endothelial cell O-glycan deficiency causes blood/lymphatic misconnections and consequent fatty liver disease in mice. J Clin Invest 2008;118(11):3725–3737.https://doi.org/10.1172/JCI36077
- Sekiguchi T, Takemoto A, Takagi S, Takatori K, Sato S, Takami M, Fujita N. Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget 2016;7(4):3934–3946. https://doi.org/10.18632/oncotarget.6598
- Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, Osawa M, Tsuruo T. Molecular Identification of Aggrus/T1α as a platelet aggregation-inducing factor expressed in Colorectal Tumors. J Biol Chem 2003; 278(51): 51599–51605.https://doi.org/10.1074/jbc.M309935200
- Krishnan H, Ochoa-Alvarez JA, Shen Y, Nevel E, Lakshminarayanan M, Williams MC, Ramirez MI, Miller WT, Goldberg GS. Serines in the intracellular tail of podoplanin (PDPN) regulate cell motility. J Biol Chem 2013;288(17):12215–12221.https://doi.org/10.1074/jbc.C112.446823
- Zelensky AN, Gready JE. The C-type lectin-like domain superfamily. Febs J 2005;272(24):6179–6217. https://doi.org/10.1111/j.1742-4658.2005.05031.x
- Tsukiji N, Osada M, Sasaki T, Shirai T, Satoh K, Inoue O, Umetani N, Mochizuki C, Saito T, Kojima S, et al. Cobalt hematoporphyrin inhibits CLEC-2–podoplanin interaction, tumor metastasis, and arterial/venous thrombosis in mice. Blood Advances 2018;2(17):2214–2225.https://doi.org/10.1182/bloodadvances.2018016261
- Kardeby C, Falker K, Haining EJ, Criel M, Lindkvist M, Barroso R, Pahlsson P, Ljungberg LU, Tengdelius M, Rainger GE, et al. Synthetic glycopolymers and natural fucoidans cause human platelet aggregation via PEAR1 and GPIbalpha. Blood Adv 2019;3(3):275–287.
- Kardeby C, Damaskinaki F-N, Sun Y, Watson SP. Is the endogenous ligand for PEAR1 a proteoglycan: clues from the sea. Platelets 2021:32(6):779–785. doi:https://doi.org/10.1080/09537104.2020.1863938
- Alshehri OM, Montague S, Watson S, Carter P, Sarker N, Manne B, Miller JC, Herr A, Pollitt A, O’Callaghan C, et al. Activation of glycoprotein VI (GPVI) and C-type lectin-like receptor-2 (CLEC-2) underlies platelet activation by diesel exhaust particles and other charged/hydrophobic ligands. Biochem J 2015; 468(3): 459–473.https://doi.org/10.1042/BJ20150192
- Manne BK, Getz TM, Hughes CE, Alshehri O, Dangelmaier C, Naik UP, Watson SP, Kunapuli SP. Fucoidan is a novel platelet agonist for the C-type lectin-like receptor 2 (CLEC-2). J Biol Chem 2017; 130(20):7717–7726. https://doi.org/10.1074/jbc.M112.424473
- Radaev S, Sun PD. Structure and function of natural killer cell surface receptors. Annu Rev Biophys Biomol Struct 2003;32(1):93–114. https://doi.org/10.1146/annurev.biophys.32.110601.142347
- Ogasawara S, Kaneko MK, Price JE, Kato Y. Characterization of anti-podoplanin monoclonal antibodies: critical epitopes for neutralizing the interaction between podoplanin and CLEC-2. Hybridoma (Larchmt) 2008; 27(4): 259–267. https://doi.org/10.1089/hyb.2008.0017
- Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, Chiba Y, Hasegawa Y, Hirabayashi J, Narimatsu H, Mishima K, et al. Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 2006;349(4):1301–1307. https://doi.org/10.1016/j.bbrc.2006.08.171
- Takagi S, Sato S, Oh-hara T, Takami M, Koike S, Mishima Y, Hatake K, Fujita N. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS One 2013;8(8):e73609.https://doi.org/10.1371/journal.pone.0073609
- Ukaji T, Takemoto A, Katayama R, Takeuchi K, Fujita N. A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis). Oncotarget 2018;9(70):33322–33336. https://doi.org/10.18632/oncotarget.26055
- Lorenz V, Stegner D, Stritt S, Vögtle T, Kiefer F, Witke W, Schymeinsky J, Watson SP, Walzog B, Nieswandt B, et al. Targeted downregulation of platelet CLEC-2 occurs through Syk-independent internalization. Blood 2015;125(26):4069–4077. https://doi.org/10.1182/blood-2014-11-611905
- Shirai T, Inoue O, Tamura S, Tsukiji N, Sasaki T, Endo H, Satoh K, Osada M, Sato-Uchida H, Fujii H, et al. C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. J Thromb Haemost 2017;15(3):513–525. https://doi.org/10.1111/jth.13604